HDAC9 and neoplasm: The limitations of HDACis in the past for treating glioblastoma lie in its side effects - it can cause fatigue, thrombocytopenia and gastrointestinal problems, not all HDAC inhibitors have good BBB penetration ability, tumor cells can easily develop acquired resistance through multiple mechanisms, and HDACis are usually not highly selective (Yang et al., 2025).